Drug Trial Radar · NCT05454098
Clifutinib Food Effect Study in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Mar 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Nov 8, 2022
Primary completion
Dec 8, 2022
Study completion Dec 8, 2022
Sponsor
- Lead sponsor
- Sunshine Lake Pharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 12, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate to determine the effect of food on the PK of a single dose of 40 mg Clifutinib in healthy subjects.
Conditions
- Acute Myeloid Leukemia in Children
Interventions
Clifutinib with fed stateDrug
40 mg Clifutinib with food
Clifutinib with fasted stateDrug
40 mg Clifutinib without food
Primary outcomes
What the sponsor says the trial is designed to measure.
- CmaxTime frame: 4 weeks
- AUC0-∞Time frame: 4 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
the First Hospital of Jilin University
Changchun, Jilin, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.